ImmunityBio (IBRX) Stock Surges 30% on 700% Revenue Growth

TLDR ImmunityBio shares jumped 30.79% Thursday after preliminary 2025 results showed Anktiva revenue surged 700% to $113 million Q4 2025 revenue reached $38.3 million, representing a 20% sequential increase and 431% year-over-year growth Saudi FDA approved Anktiva for metastatic non-small cell lung cancer and BCG-unresponsive bladder cancer Analysts maintain Strong Buy ratings with a $7.33 [...]

The post ImmunityBio (IBRX) Stock Surges 30% on 700% Revenue Growth appeared first on Blockonomi.